The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy
Open accessAbstract
BACKGROUND: American Thyroid Association guidelines currently recommend the selective use of radioactive iodine (RAI) therapy in patients with well differentiated thyroid cancer (WDTC). Despite these guidelines, RAI ablation has been used routinely in all but the very lowest risk patients with thyroid cancer over the last 30 years. The objective of this study was to evaluate patterns of RAI use and elevated risk of secondary primary malignancies (SPM) in patients with low‐risk (T1N0) WDTC. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to analyze trends in RAI use over time in the United States. To determine the excess risk of SPM, the standardized incidence ratio (SIR) and excess absolute risk (EAR) of various cancers were calculated in the 2 cohorts. Between 1973 and 2007, 37,176 patients with WDTC were followed in the SEER Program, equating to 408,750 person‐years at risk (PYR). In total, 14,589 patients received RAI, and SPMs were observed in 3223 patients. RESULTS: During the study period, the rate of RAI use in patients with low‐risk (T1N0) WDTC increased from 3.3% to 38.1%. For low‐risk patients, the SIR of SPM was 1.21 (95% confidence interval [CI], 0.93‐1.54), and the EAR was 4.6 excess cases per 10,000 PYR. SPM with significantly elevated risk because of RAI were salivary gland malignancies (SIR = 11.13; 95% CI, 1.35‐40.2) and leukemia (SIR = 5.68; 95% CI, 2.09‐12.37). The excess risk of leukemia was significantly greater in patients aged <45 years (SIR = 5.32; 95% CI, 2.75‐9.30) compared with the excess risk in older patients (SIR = 2.26; 95% CI, 1.43‐3.39). CONCLUSIONS: The increased risk of a SPM in patients with low‐risk (T1N0) WDTC, along with a lack of data demonstrating improved survival outcomes with adjuvant RAI, provide a compelling argument in favor of rationing the use of RAI in this patient population. Cancer 2011;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707 · cited 4×
“Existing guidelines from the American Thyroid Association (ATA) cite these factors.(7) Notwithstanding available data and guidelines, there is widespread use of RAI in patients who have a low risk of recurrence.”
BackgroundInfluentialSelf-citationIncreasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Multiple primary malignant tumors. A survey of the literature and a statistical study
Warren, S. (1932) · American Journal of Cancer · Cited by 2,554
Papillary and Follicular Thyroid Carcinoma
Schlumberger, M. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380506 · Cited by 1,623
Welch, H. G., & Black, W. C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq099 · Cited by 1,599
Jemal, A., Thun, M. J., Ries, L. A. G., Howe, H. L., Weir, H. K., Center, M. M., Ward, E., Wu, X.-C., Eheman, C., Anderson, R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn389 · Cited by 957
Hay, I. D., Thompson, G. B., Grant, C. S., Bergstralh, E. J., Dvorak, C. E., Gorman, C. A., Maurer, M. S., McIver, B., Mullan, B. P., Oberg, A. L., et al. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6612-1 · Cited by 736
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 727
Second primary malignancies in thyroid cancer patients
Rubino, C., de Vathaire, F., Dottorini, M. E., Hall, P., Schvartz, C., Couette, J. E., Dondon, M. G., Abbas, M. T., Langlois, C., & Schlumberger, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601319 · Cited by 655
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404
Self-citationGuidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
Mallick, U., Harmer, C., Yap, B., Wadsley, J., Clarke, S., Moss, L., Nicol, A., Clark, P. M., Farnell, K., McCready, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109589 · Cited by 615
Bonnema, S. J., & Hegedüs, L. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1030 · Cited by 339
Thyroid Lobectomy for Papillary Thyroid Cancer: Long‐term Follow‐up Study of 1,088 Cases
Matsuzu, K., Sugino, K., Masudo, K., Nagahama, M., Kitagawa, W., Shibuya, H., Ohkuwa, K., Uruno, T., Suzuki, A., Magoshi, S., et al. (2014) · World Journal of Surgery · doi:10.1007/s00268-013-2224-1 · Cited by 331
Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours
Brito, J. P., Morris, J. C., & Montori, V. M. (2013) · BMJ · doi:10.1136/bmj.f4706 · Cited by 323
New developments in the diagnosis and treatment of thyroid cancer
Schneider, D. F., & Chen, H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21195 · Cited by 316
Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.4011 · Cited by 313
A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up
Grogan, R. H., Kaplan, S. P., Cao, H., Weiss, R. E., DeGroot, L. J., Simon, C. A., Embia, O. M. A., Angelos, P., Kaplan, E. L., & Schechter, R. B. (2013) · Surgery · doi:10.1016/j.surg.2013.07.008 · Cited by 301
Ruel, E., Thomas, S., Dinan, M., Perkins, J. M., Roman, S. A., & Sosa, J. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4332 · Cited by 268
Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Advani, A. S., Gerds, A. T., Carraway, H. E., Angelini, D., Kalaycio, M., Nazha, A., Adelstein, D. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.0232 · Cited by 154
Metadata
- Authors
- Iyer, N. G., Morris, L. G. T., Tuttle, R. M., Shaha, A. R., & Ganly, I.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-03-22
- Volume
- 117
- Issue
- 19
- Pages
- 4439-4446
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2098724902
- Cited by
- 321
- References
- 26
- FWCI
- 20.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.